This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Alaven Pharmaceutical LLC
Alaven Pharmaceutical LLC, a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2002, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. With a strong operational presence across North America, Alaven focuses on delivering innovative solutions in the areas of pain management, anti-infectives, and other therapeutic categories. Alaven's core products are distinguished by their commitment to quality and efficacy, ensuring they meet the rigorous standards of healthcare providers and patients alike. The company has achieved notable milestones, including strategic partnerships that enhance its market position and expand its product offerings. With a reputation for reliability and excellence, Alaven Pharmaceutical LLC continues to make significant contributions to the healthcare landscape.
DitchCarbon Score
How does Alaven Pharmaceutical LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alaven Pharmaceutical LLC's score of 45 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alaven Pharmaceutical LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Viatris Inc., which means that any emissions data or climate commitments may be inherited from its parent organisation. As of now, Alaven Pharmaceutical LLC has not publicly disclosed any specific reduction targets or initiatives related to carbon emissions. However, it is important to note that Viatris Inc. has established various climate commitments and initiatives that may influence Alaven's sustainability strategies. Given the absence of direct emissions data and reduction targets, Alaven Pharmaceutical LLC's climate commitments remain unclear. The company may benefit from aligning with the broader sustainability goals set by Viatris Inc., which could include participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). In summary, while Alaven Pharmaceutical LLC does not currently report specific emissions data or reduction targets, its affiliation with Viatris Inc. suggests potential alignment with industry-standard climate initiatives and commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 302,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alaven Pharmaceutical LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
